NCT06905834View on ClinicalTrials.gov

Evaluation of Allogenic Mesenchymal Stem Cell (MSC) Injection Therapy for Refractory Graft-versus-Host Disease (GVHD) Unresponsive to Conventional Treatments

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

June 30, 2025

Primary Completion Date

June 30, 2027

Study Completion Date

June 30, 2028

Conditions
Dry Eye Disease (DED)Graft-Versus-Host Disease(GVHD)
Interventions
DRUG

Subconjuntival injection of expanded allogenic adult adipose tissue-derived mesenchymal stem cells (ASC

Subconjunctival injection is a widely used technique in ophthalmology due to its effectiveness, minimal invasiveness, and ease of administration. In a subconjunctival injection the cells adult adipose tissue-derived mesenchimal cells are delivered into the subconjunctival space, the area between the conjunctiva and sclera.

All Listed Sponsors
collaborator

Spanish Clinical Research Network - SCReN

NETWORK

collaborator

Instituto Universitario de Oftalmobiología Aplicada (Institute of Applied Ophthalmobiology) - IOBA

OTHER

lead

Instituto de Investigación Biomédica de Salamanca

OTHER